As spring arrives, the 13th National Conference on Hematopoietic Stem Cell Transplantation of the Chinese Medical Association, hosted by the Chinese Medical Association and organized by the National Clinical Research Center for Hematologic Diseases-Peking University Institute of Hematology, was grandly held in Beijing from March 1st to 2nd. This conference focused comprehensively on hematopoietic stem cell transplantation, bringing together many renowned experts in the field of hematology from both domestic and international arenas. Centered around the basic and clinical research of hematopoietic stem cell transplantation, the conference covered various topics including advancements in transplantation indications, new transplantation models, prevention and treatment strategies for transplantation complications and relapse, progress in basic research, and transplantation-related clinical trials. During the conference, Oncology Frontier – Hematology Frontier had the honor to interview Professor Xiaohui Zhang from Peking University People’s Hospital, who shared the significant progress made in the field of hematopoietic stem cell transplantation in China in recent years.
Oncology Frontier – Hematology Frontier: As an authoritative expert in the field of hematopoietic stem cell transplantation in China, could you please discuss the recent developments or milestone events in the field of hematopoietic stem cell transplantation in our country?
Professor Xiaohui Zhang: Since completing the first hematopoietic stem cell transplantation in the 1960s, China has progressed from lagging behind in technology and academia to running abreast and leading in many aspects of hematopoietic stem cell transplantation, with Academician Huang Xiaojun taking the lead. This not only reflects the wisdom of the Chinese people but also represents the collective efforts of all hematologists. In this process, there are several points I believe we have done very well:
Firstly, continuous improvement and optimization have been made on the basis of the Beijing protocol, with the expansion of indications being one of the manifestations. Breakthroughs in transplantation technology have brought good news to patients with severe hematologic diseases other than malignant tumors, such as severe aplastic anemia and Fanconi anemia;
Secondly, through continuous improvement and optimization, the hematopoietic stem cell transplantation protocol in China has been greatly improved;
Another point is that the Beijing protocol has been widely promoted and popularized globally, from initial skepticism to recognition, approval, simulation, and adoption at the international level. The Beijing protocol has been recognized by transplanters and hematologists worldwide, which I believe is a great contribution to the field of hematology in China and the world. Based on this, Academician Huang Xiaojun recently received the Outstanding Service Award from the International Hematopoietic and Bone Marrow Transplantation Research Center, making him the only recipient of this award in Asia at present. In summary, all of this has been hard-won and reflects the strong innovation capabilities behind it.
Professor Xiaohui Zhang
Chief Physician, Professor, Doctoral/Postdoctoral Supervisor
Deputy Director of Hematology, Peking University People’s Hospital, and Deputy Director of Peking University Institute of Hematology
Deputy Director of the Hematology Branch Committee of the Chinese Medical Association and Leader of the Hematopoietic Stem Cell Application Group
Deputy Director of the Hematology Immunology Committee of the Chinese Society of Immunology
Chairman of the Hematology Working Committee of the Beijing Cancer Prevention and Treatment Society
Principal Investigator of National Science and Technology Major Projects, Key Projects of the National Natural Science Foundation, and Key Research Projects in the Capital Health Development
Lead Author/Coordinator of 29 Chinese expert guidelines/consensuses, Editor-in-Chief of 5 monographs in the field of hematology, and holder of 14 national invention patents (applications/grants)
First/corresponding author of 125 SCI papers published in journals such as Nat. Immunol, J Hematol Oncol, Lancet Hematol, Blood, Nat. Commun, Am J Hematol, Leukemia, etc.
Recipient of the “Famous Physician of the Nation” and “Outstanding Achievement” titles; First prize winner of the Huaxia Medical Science and Technology Award; Second prize winner of the Chinese Medical Science and Technology Award; Co-winner of the National Science and Technology Progress Award (2 awards)
